Compare MAS & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MAS | DVA |
|---|---|---|
| Founded | 1929 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Misc Health and Biotechnology Services |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.4B | 14.9B |
| IPO Year | 1994 | 2003 |
| Metric | MAS | DVA |
|---|---|---|
| Price | $82.76 | $161.80 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 22 | 8 |
| Target Price | $82.74 | ★ $222.29 |
| AVG Volume (30 Days) | ★ 2.1M | 753.7K |
| Earning Date | 10-28-2026 | 10-29-2026 |
| Dividend Yield | ★ 1.55% | N/A |
| EPS Growth | ★ 2.66 | N/A |
| EPS | 3.81 | ★ 10.27 |
| Revenue | $7,562,000,000.00 | ★ $13,643,069,000.00 |
| Revenue This Year | $1.98 | $4.38 |
| Revenue Next Year | $2.08 | $3.66 |
| P/E Ratio | $21.72 | ★ $15.21 |
| Revenue Growth | N/A | ★ 6.46 |
| 52 Week Low | $58.16 | $101.00 |
| 52 Week High | $87.86 | $247.49 |
| Indicator | MAS | DVA |
|---|---|---|
| Relative Strength Index (RSI) | 55.77 | 35.65 |
| Support Level | $67.29 | $145.58 |
| Resistance Level | $82.97 | $194.64 |
| Average True Range (ATR) | 2.40 | 6.41 |
| MACD | -0.54 | -3.03 |
| Stochastic Oscillator | 14.11 | 20.65 |
Masco is a global manufacturer of branded home improvement products, with a focus on plumbing fixtures (70% of revenue) and decorative architectural coatings (30% of revenue). The company primarily serves the repair and remodel market, with products such as faucets, showerheads, and paint sold through retail, wholesale, and e-commerce channels. Its portfolio includes well-known brands such as Delta, Hansgrohe, and Behr.
DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%. The firm operates over 3,200 facilities worldwide, mostly in the US, and treats about 300,000 patients annually. Government payers dominate US dialysis reimbursement. DaVita receives about two-thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.